Oncothyreon (ONTY) ONT-380 Data Supports Further Development After a Confusing Call/Press Release - Jefferies
Get Alerts ONTY Hot Sheet
Rating Summary:
7 Buy, 2 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 13 | New: 18
Join SI Premium – FREE
Jefferies analyst Biren Amin reiterated a Buy rating and $5 price target on Oncothyreon (NASDAQ: ONTY), which is down 21% following a confusing call and press release.
Amin commented, "ONTY issued a press release and held a conference that confused many investors regarding the data but ultimately clarified the situation by providing full ONT-380 data to be presented Friday at SABCS. ONTY presented updated data in 12 evaluable pts with metastatic breast cancer and CNS metastasis and reported a 33% ORR in combination w/ Kadcyla. ONTY also plans to initiate a PIIb combo trial with Herceptin and Xeloda and will initiate by YE '15."
For an analyst ratings summary and ratings history on Oncothyreon click here. For more ratings news on Oncothyreon click here.
Shares of Oncothyreon closed at $3.13 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Inspire Medical (INSP), ResMed (RMD) on Watch Following Report on Sleep Apnea
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- CSX Corp. (CSX) Shares Trade Lower Ahead of Results, Down 2.2%
Create E-mail Alert Related Categories
Analyst Comments, FDA, Trader TalkRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!